Clinical Trials on Recurrent Anal Cancer in Canada

Total 3962 results

National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

Canada
GOG Foundation
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7

United States, Canada, Japan
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme

United States, Belgium, Australia, Spain, France, Canada
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
NRG Oncology
National Cancer Institute (NCI)

Completed

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Prostate Adenocarcinoma | Stage IV Breast Cancer | Recurrent Breast Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Male Breast Carcinoma

United States, Canada, Switzerland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Rebiotix Inc.

Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD2)

Enterocolitis Clostridium Difficile Recurrent

United States, Canada
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Cancer

United States, Canada
SpectraCure AB

Recruiting

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Recurrent Prostate Cancer

United States, Canada, United Kingdom, Sweden
The Hospital for Sick Children

Completed

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors (COZMOS)

Childhood Solid Tumor | Recurrent Childhood CNS Tumor | Ependymoma, Recurrent Childhood

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Cancer AJCC v7 | Stage IVB Major Salivary Gland Cancer AJCC v7 | Stage IVC Major Salivary Gland Cancer AJCC v7 | Tongue Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Recurrent Oral Cavity Adenoid Cystic Carcinoma | Stage... and other conditions

United States, Canada
National Cancer Institute (NCI)

Terminated

RO4929097 in Treating Patients With Recurrent Invasive Gliomas

Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Adult Brain Stem Glioma

Canada
Alpha Tau Medical LTD.

Recruiting

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma

United States, Israel, Canada
OSI Pharmaceuticals

Terminated

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY)

Recurrent or Refractory Pediatric Ependymoma

United States, Canada, United Kingdom
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Recurrent and Refractory Solid Tumors

United States, Canada
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Recurrent Prostate Cancer | Hormone Refractory Prostate Cancer

United States, Canada
National Cancer Institute (NCI)

Terminated

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditions

Canada
St. Jude Children's Research Hospital
Pfizer; Ipsen

Active, not recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Peripheral Primitive Neuroectodermal Tumor | Recurrent Rhabdoid Tumor | Recurrent... and other conditions

United States, Canada
Rabin Medical Center
University of Toronto

Completed

Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer (FPSAR)

Death | Metastasis | Castration-resistant Prostate Cancer

Canada
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma

United States, Canada
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Recurrent Thyroid Cancer | Recurrent Childhood Rhabdomyosarcoma | Papillary Thyroid Cancer | Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Liver Cancer | Childhood Hepatocellular Carcinoma

United States, Canada, Australia
University of California, San Francisco
Genentech, Inc.

Active, not recruiting

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas

United States, Canada
Colon and Rectal Surgery Associates, Ltd.
Massachusetts General Hospital; University of Pennsylvania; University of Ottawa

Unknown

Ligation of Intersphincteric Fistula Tract (LIFT) Procedure Versus Use of an Anal Fistula Plug for Anal Fistula Repair (LIFT vs PLUG)

Anal Fistula

United States, Canada
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
Canadian Urology Research Consortium
Ferring Pharmaceuticals

Terminated

Firmagon (Degarelix) Intermittent Therapy (FIT)

Prostate Cancer Recurrent

Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Cervical Adenosquamous Cell Carcinoma

Canada
National Cancer Institute (NCI)

Completed

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Recurrent Osteosarcoma | Metastatic Osteosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | High Risk Neuroblastoma | Resectable Osteosarcoma

United States, Canada
University Health Network, Toronto

Active, not recruiting

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer | Recurrent | Platinum-resistant

Canada
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma | Refractory Childhood Hodgkin Lymphoma | Recurrent Childhood Hodgkin Lymphoma

United States, Canada
Ottawa Hospital Research Institute

Recruiting

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Prostate Cancer

Canada
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma

United States, Canada
AstraZeneca

Completed

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL)

Recurrent Glioblastoma

United States, Australia, France, United Kingdom, Germany, Netherlands, Canada, Austria, Belgium, Czech Republic
National Cancer Institute (NCI)

Recruiting

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Ewing Sarcoma | Recurrent Alveolar Rhabdomyosarcoma | Refractory Alveolar Rhabdomyosarcoma

United States, Canada
Centre hospitalier de l'Université de Montréal...
University of British Columbia; Unity Health Toronto; Penn State University; University... and other collaborators

Recruiting

Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence (h-APC_EMR)

Colorectal Cancer | Polyp of Colon

Canada
Lawson Health Research Institute
Canadian Institutes of Health Research (CIHR)

Completed

Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer (IGPC-3)

Prostate Cancer

Canada
National Cancer Institute (NCI)

Completed

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Completed

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

Canada
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Intraocular Melanoma | Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Extraocular Extension Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Superficial... and other conditions

Canada
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditions

Canada
National Cancer Institute (NCI)

Completed

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Helsinn Healthcare SA
Labcorp Drug Development Inc

Withdrawn

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NEWEL)

Advanced Solid Tumor | CNS Tumor | Recurrent WHO Grade II Glioma

United States, Canada, Germany
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer

Anal Cancer

United States, Canada

Clinical Trials on Recurrent Anal Cancer in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations